These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 8105108)
21. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Nakamura T; Nekarda H; Hoelscher AH; Bollschweiler E; Harbeck N; Becker K; Siewert JR; Harbec N [corrected to Harbeck N] Cancer; 1994 Apr; 73(7):1785-94. PubMed ID: 7907940 [TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Kihana T; Tsuda H; Teshima S; Nomoto K; Tsugane S; Sonoda T; Matsuura S; Hirohashi S Cancer; 1994 Jan; 73(1):148-53. PubMed ID: 7506116 [TBL] [Abstract][Full Text] [Related]
23. Distribution and patterns of staining of Neu oncogene product in benign and malignant breast diseases. Hanna W; Kahn HJ; Andrulis I; Pawson T Mod Pathol; 1990 Jul; 3(4):455-61. PubMed ID: 1977159 [TBL] [Abstract][Full Text] [Related]
24. Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. Lipponen P Eur J Cancer; 1993; 29A(5):749-53. PubMed ID: 8097100 [TBL] [Abstract][Full Text] [Related]
25. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Velasco A; Hewitt SM; Albert PS; Hossein M; Rosenberg H; Martinez C; Sagalowsky AI; McConnell JD; Marston W; Leach FS Cancer; 2002 Feb; 94(3):690-9. PubMed ID: 11857301 [TBL] [Abstract][Full Text] [Related]
26. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Morote J; de Torres I; Caceres C; Vallejo C; Schwartz S; Reventos J Int J Cancer; 1999 Aug; 84(4):421-5. PubMed ID: 10404097 [TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Têtu B; Brisson J Cancer; 1994 May; 73(9):2359-65. PubMed ID: 7909490 [TBL] [Abstract][Full Text] [Related]
30. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Travis A; Pinder SE; Robertson JF; Bell JA; Wencyk P; Gullick WJ; Nicholson RI; Poller DN; Blamey RW; Elston CW; Ellis IO Br J Cancer; 1996 Jul; 74(2):229-33. PubMed ID: 8688326 [TBL] [Abstract][Full Text] [Related]
31. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Wright C; Angus B; Nicholson S; Sainsbury JR; Cairns J; Gullick WJ; Kelly P; Harris AL; Horne CH Cancer Res; 1989 Apr; 49(8):2087-90. PubMed ID: 2564806 [TBL] [Abstract][Full Text] [Related]
32. c-erbB-3 protein expression in ovarian tumours. Simpson BJ; Weatherill J; Miller EP; Lessells AM; Langdon SP; Miller WR Br J Cancer; 1995 Apr; 71(4):758-62. PubMed ID: 7710941 [TBL] [Abstract][Full Text] [Related]
33. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304 [TBL] [Abstract][Full Text] [Related]
34. Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma. Lee EY; Cibull ML; Strodel WE; Haley JV Arch Pathol Lab Med; 1994 Mar; 118(3):235-9. PubMed ID: 7907854 [TBL] [Abstract][Full Text] [Related]
35. C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. Porter PL; Garcia R; Moe R; Corwin DJ; Gown AM Cancer; 1991 Jul; 68(2):331-4. PubMed ID: 1676930 [TBL] [Abstract][Full Text] [Related]
36. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Lipponen P; Eskelinen M Br J Cancer; 1994 Jun; 69(6):1120-5. PubMed ID: 7911031 [TBL] [Abstract][Full Text] [Related]
37. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Bodey B; Bodey B; Gröger AM; Luck JV; Siegel SE; Taylor CR; Kaiser HE Anticancer Res; 1997; 17(2B):1319-30. PubMed ID: 9137492 [TBL] [Abstract][Full Text] [Related]
38. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer. Kerns BJ; Jordan PA; Huper G; Marks JR; Iglehart JD; Layfied LJ Mod Pathol; 1993 Nov; 6(6):673-8. PubMed ID: 7905629 [TBL] [Abstract][Full Text] [Related]
39. c-erB-2 oncoprotein expression in malignant and nonmalignant breast tissue. McCann A; Johnston PA; Dervan PA; Gullick WJ; Carney DN Ir J Med Sci; 1989 Jun; 158(6):137-40. PubMed ID: 2570047 [TBL] [Abstract][Full Text] [Related]
40. Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues. Ibrahim GK; MacDonald JA; Kerns BJ; Ibrahim SN; Humphrey PA; Robertson CN Surg Oncol; 1992 Apr; 1(2):151-5. PubMed ID: 1285216 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]